A patient with stage IV gastric cancer who acquired complete remission after undergoing multi-peptide dendritic cell immunotherapy in combination with standard therapies

In this report, we describe a 62-year-old male patient with stage IV gastric cancer who was treated with chemotherapy and dendritic cell immunotherapy targeting the cancer antigens WT1, MUC1, Her-2, and survivin. He then received WT1 and MUC1 peptides in combination with adjuvants near the lymph nodes or the mucosa of the cancer lesion. Subsequently, a remarkable decrease in the size of the gastric lesion, in the swelling of metastatic lymph nodes, and the disappearance of ascites were observed. After 1 year and 2 months of the initial diagnosis, the patient underwent a robot-assisted gastrectomy and was able to return to work. In conclusion, multi-peptide dendritic cell immunotherapy in combination with conventional therapies resulted in remarkable anti-cancer effects and improved the patient's quality of life.